Fosamax® Litigation at The Lanier Law Firm
Fosamax® (Alendronate Sodium) is a member of a class of drugs known as "bisphosphonates." Manufactured by Merck & Co., Fosamax was approved by the U.S. Food and Drug Administration in 1995, and is commonly used to treat patients with osteoporosis and Paget's disease.
Fosamax and other bisphosphonates, including Aredia® and Zometa®, have been linked to a serious bone disease called Osteonecrosis of the Jaw, or ONJ, also known as "Dead Jaw" or "Jaw Death." ONJ involves the breakdown or death of the jaw bone, frequently leading to infection or fractures and requiring long term care.
Following a study published in the Journal of Oral and Maxillofacial Surgeons, the FDA issued a warning to healthcare professionals in August 2004 regarding bisphosphonate therapy and its side effects.
If you or a loved one has used Fosamax and suffered side effects, please contact our office for a free evaluation.
Fosamax Information Links:
"Drug Linked to Death of Jaw Bone", USA Today, March 13, 2005.
